WASHINGTON (CNS) The chairman of the U.S. bishops pro-life committee April 20 called on the Biden administration to fund research that does not rely upon body parts taken from innocent children killed through abortion.
The bodies of children killed by abortion deserve the same respect as that of any other person, said Archbishop Joseph F. Naumann of Kansas City, Kansas, chairman of the U.S. Conference of Catholic Bishops Committee on Pro-Life Activities.
Our government has no right to treat innocent abortion victims as a commodity that can be scavenged for body parts to be used in research, he said.
His remarks were a reaction to a notice the National Institutes of Health in Bethesda, Maryland, posted April 16 in the grants area of its website announcing the end of a Trump administration ban on research involving human fetal tissue acquired from elective abortions.
In addition, NIH and the U.S. Department of Health and Human Services will no longer convene the Human Fetal Tissue Research Ethics Advisory Board.
Under President Donald Trump, the two agencies had established the board to review research applications for NIH grants, cooperative agreements, and research and development contracts that proposed using fetal tissue from elective abortions.
The previous administration also terminated contracts without outside institutions that used fetal stem cells for research.
According to Roll Call, a news outlet on Capitol Hill, the decision to lift the ban came after 26 House Democrats wrote to HHS Secretary Xavier Becerra, urging this policy change.
It is unethical to promote and subsidize research that can lead to legitimizing the violence of abortion, Archbishop Naumann said in his statement. Researchers have demonstrated that we can do effective scientific research and develop efficacious clinical treatments without harvesting tissue from aborted babies.
It is also deeply offensive, he added, to millions of Americans for our tax dollars to be used for research that collaborates with an industry built on the taking of innocent lives.
Other pro-life reaction to NIHs announcement included a statement from Tom McClusky, president of March for Life Action, the sister organization of the March for Life Education and Defense Fund.
He said the Biden administrations decision to fund research that requires aborted fetal tissue (is) very disappointing.
This type of experimental research is a gross violation of human dignity and is not where the majority of Americans want their tax dollars being spent, McClusky said. The government has no business creating a marketplace for aborted baby body parts.
It is a move in the wrong direction, agreed Tara Sander Lee, senior fellow and director of life sciences at Charlotte Lozier Institute, which is the research and education arm of the Susan B. Anthony List.
There are superior and ethical alternatives available such as adult stem-cell models being used by countless scientists worldwide to develop and produce advanced medicines treating patients now, without exploitation of any innocent life, she said. All scientists should reject the administrations attempts to prey on fears related to the pandemic to advance the practice of harvesting fetal tissue.
Pro-abortion Democrats push this deeply unpopular agenda at their own political peril, said Marjorie Dannenfelser, president of the Susan B. Anthony List.
The HHS ban on NIH using human fetal stem cells in research announced June 5, 2020, came after an audit and review of its own research involving human fetal tissue and elective abortions. Regarding contracts with outside institutions, HHS refused to renew a $13 million research contract with the University of California, San Francisco, because it failed to live up to it moral and ethical standards.
In 2019 alone, NIH spent $120 million on fetal tissue of unborn babies, according to a news release issued by HHS at the time.
Meanwhile in Congress, ahead of the April 16 announcement by NIH, Rep. Chris Smith, R-N.J., spoke during debate on a bill to reauthorize the Stem Cell Therapeutic and Research Act of 2005. Smith was the prime sponsor of the 2005 bill and of a bill to reauthorize it in 2015.
The new law created a nationwide umbilical cord blood stem-cell program, designed to collect, derive, type and freeze cord blood units for transplantation into patients to mitigate and to even cure serious disease, Smith said April 14.
Pursuant to the law, it also provided stem cells for research he said, adding that new cord blood program was combined with an expanded bone marrow initiative, whose main sponsor was the late Rep. C.W. Bill Young, R-Fla.
The reauthorization bill for the Stem Cell Therapeutic and Research Act authorizes $23 million to be appropriated for fiscal year 2021 through fiscal year 2025. It also authorizes $30 million to be appropriated for fiscal years 2021 through 2025 for the bone marrow transplant program.
This continues funding at the same levels authorized in the 2015 authorization bill, Smith said.
Each year, nearly 4 million babies are born in America. In the past, virtually every placenta and umbilical cord was tossed as medical waste, Smith said in his comments on the floor. Today, doctors have turned this medical waste into medical miracles.
Not only has God in his wisdom and goodness created a placenta and umbilical cord to nurture and protect the precious life of an unborn child, he continued, but now we know that another gift awaits us immediately after birth. Something very special is left behind cord blood that is teeming with lifesaving stem cells.
According to Smith, one of the best kept secrets in America is umbilical cord blood stem cells and adult stem cells in general are curing people of a myriad of terrible conditions and diseases over 70 diseases in adults as well as in children.
Follow Asher on Twitter: @jlasher
Read more from the original source:
Research with fetal tissue from elective abortion called 'deeply offensive' - Catholic News Service
- Different Types Of Stem Cells: Embryonic Vs. Adult ... - January 17th, 2025
- Rejuvenation of Aging Adult Stem Cells to Improve their Regenerative Potential - Frontiers - January 13th, 2025
- Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem Cell Therapy for Juvenile Idiopathic Arthritis - Business... - December 22nd, 2024
- What Are Stem Cells? Biomedical Beat Blog National Institute of ... - November 29th, 2024
- TVHS opens stem cell processing lab to expand biotherapies | VA Tennessee Valley health care | Veterans Affairs - Veterans Affairs - November 8th, 2024
- Understanding Mature Tissue or Organ Stem Cells and Their Clinical ... - November 8th, 2024
- Biology of stem cells: an overview - PMC - PubMed Central (PMC) - October 30th, 2024
- New government tech deals boost the business of cancer detection - GOV.UK - October 11th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - Yahoo News UK - October 11th, 2024
- Advances in different adult stem cell-derived exosomal non-coding RNAs for the treatment of neurological disorders: a narrative review - Frontiers - September 26th, 2024
- Breakthrough technique may help speed understanding, treatment of MD, ALS - Harvard Gazette - September 14th, 2024
- Rostock University Explores Use of Stem Cells for Meat Cultivation with Help from Innocent Meat - vegconomist - the vegan business magazine - August 12th, 2024
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - July 31st, 2024
- Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - July 31st, 2024
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - July 31st, 2024
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 - July 31st, 2024
- Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024 - July 31st, 2024
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 - July 31st, 2024
- Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency... - July 31st, 2024
- Targeting the stem cell niche micro-environment as therapeutic strategies in aging - Frontiers - June 28th, 2024
- International trial introduces another curative option for sickle cell disease - EurekAlert - June 28th, 2024
- HOX genes in stem cells: Maintaining cellular identity and regulation of differentiation - Frontiers - June 28th, 2024
- Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and... - June 21st, 2024
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management - June 21st, 2024
- Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. - June 21st, 2024
- Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Samer Kaba, MD as Chief Medical Officer - June 21st, 2024
- API and the University of Alberta Break Ground in Edmonton on Canada’s Largest Manufacturing Facility for Critical Medicines - June 21st, 2024
- Syntekabio Signs Memorandum of Understanding with bioSeedin/ACROBiosystems - June 21st, 2024
- Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform - June 21st, 2024
- Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog... - June 21st, 2024
- Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting - June 21st, 2024
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing - June 21st, 2024
- NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran - June 21st, 2024
- Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’... - June 21st, 2024
- Radiopharm Receives Strategic Investment for up to A$18 million - June 21st, 2024
- Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee - June 21st, 2024
- Trading by management and close relations of management - June 21st, 2024
- Major shareholder announcement - June 21st, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - June 21st, 2024
- Nature retracts highly cited 2002 paper that claimed adult stem cells could become any type of cell - Retraction Watch - June 19th, 2024
- Shares of Biotech MicroCap Rip on Licensing Talks - The Globe and Mail - June 15th, 2024
- Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024 - May 23rd, 2024
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 23rd, 2024
- Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist... - May 23rd, 2024
- Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus... - May 23rd, 2024
- Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 - May 23rd, 2024
- New York Blood Center Enterprises Celebrates the Expansion of Cell & Gene Therapy GMP Manufacturing Capabilities at the Grand Opening of... - May 23rd, 2024
- Syneos Health Leaders Recognized as PM360 ELITE 100 Award Recipients - May 23rd, 2024
- Kane Biotech Announces First Quarter 2024 Financial Results - May 23rd, 2024
- Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast - May 23rd, 2024
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy - May 23rd, 2024
- Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024 - May 23rd, 2024
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results - May 23rd, 2024
- Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - May 23rd, 2024
- Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024 - May 23rd, 2024
- Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences - May 23rd, 2024
- NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - May 23rd, 2024
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual... - May 23rd, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
Recent Comments